The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study

PHASE3CompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

March 31, 2013

Conditions
Diabetic Foot Ulcer of Neuropathic Origin
Interventions
DRUG

Trafermin 0.01% spray

For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface

Trial Locations (37)

1036

LL, Budapest

PF, Budapest

1070

Brussels

1105

Amsterdam

1407

Sofia

2625

Delft

2840

Rumst

3000

Hatvan

4000

Liège

7334

Apeldoorn

7600

Almelo

9000

Aalborg

20090

Lublin

23758

Oldenburg

45292

Trier

48145

Münster

50403

Wroclaw

50733

Cologne

51124

Wroclaw

60111

Poznan

61231

Bad Nauheim

97980

Bad Mergentheim

51 260

Crikvenica

52 100

Pula

10 000

Zagreb

62 800

Kalisz

90 302

Lodz

94 238

Lodz

70 215

Szczecin

00 132

Warsaw

65 945

Zielona Góra

929 01

Dunajská Streda

034 91

L'ubochna

940 01

Nové Zamky

952 01

Vráble

SE 205 02

EL, Malmo

Unknown

ML, Malmo

Sponsors
All Listed Sponsors
lead

Olympus Biotech Corporation

INDUSTRY